Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Relebactam (REL [MK-7655]) is a novel class A/C β-lactamase inhibitor intended for use with imipenem for the treatment of Gram-negative bacterial infections. REL restores imipenem activity against some resistant strains of Klebsiella and Pseudomonas. In this multicenter, double-blind, controlled tri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Lucasti, Christopher, Vasile, Liviu, Sandesc, Dorel, Venskutonis, Donatas, McLeroth, Patrick, Lala, Mallika, Rizk, Matthew L., Brown, Michelle L., Losada, Maria C., Pedley, Alison, Kartsonis, Nicholas A., Paschke, Amanda
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2016
Assuntos:
Clinical Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038313/
https://ncbi.nlm.nih.gov/pubmed/27503659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00633-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados